November/December 2015




Cover Focus

Ocrelizumab and the Next Phase in Multiple Sclerosis Therapy

Advances in immune therapy may change how scientists and clinicians understand neurodegenerative components of MS.

By Thomas Leist, MD, PhD

Parkinson’s Pipeline: Promise in Research and Treatment

At the Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference, experts revealed encouraging new directions in treating and understanding PD.

By Ted Pigeon, Editor-in-Chief

Managing Agitation and Aggression in Alzheimer’s Disease

Physicians should consider a range of both pharmacologic and non-pharmacologic interventions when addressing agitation.

A Q&A with Jeffrey Cummings, MD, ScD

The Emerging Role of Neurotoxins for the Treatment of Upper Limb Spasticity

One expert addresses the evolving standards of care and strategies for enabling patients to receive optimal care.

A Q&A with David M. Simpson, MD

NeuroTech: How Advances in Laser Ablation are Igniting New Approaches in Neuro-Oncology and Beyond

Amid the many technological advances in recent years, robotic laser thermotherapy has emerged as a new approach in treating brain tumors.

A Q&A with Joseph Neimat, MD

The Future of Genetics in Neurology Research and Therapy

An investigational agent under study for the treatment of neuropsychiatric disorders as well as a rare genetic disorder offers a glimpse of a new stage in neurological therapy.

With Josephine Elia, MD and Donna M. McDonald-McGinn, MS, CGC

Update in Epilepsy Therapeutics

In addition to comorbid conditions and side effects, cost and availability should factor into therapeutic selection.

Medical Marijuana: Composition, Neurological Benefits, And Adverse Events

This second in a two-part feature series on marijuana addresses the potential benefits of medical marijuana in neurology and considers future directions in care.

By Ronald Devere, MD

Expert Opinion

How to Know it When You See It: Diagnosing Neuralgic Amyotrophy (Parsonage-Turner Syndrome)

An understanding of the basic science, clinical presentation, and treatment options for neuralgic amyotrophy is necessary to facilitate timely diagnosis and treatment.

By John W. Norbury, MD, Nens van Alfen, MD, PhD, Kelly M. Harrell, PhD, MPT, Carrie A. McShane, MD, Daniel P. Moore, MD, Steven Mandel, MD

Financial Planner

Are These Three Weaknesses Lurking In Your LLC or FLP?

LLCs and FLPs can be fundamental tools for business planning, asset protection planning, family wealth planning, estate planning, and more.

By David B. Mandell, JD, MBA and Jason M. O’Dell, MS, CWM

Video case Challenge

A 70-Year-Old Man with a Sudden Lisp

By Mohanad Alzubaidi, MD and Aziz Shaibani, MD, FACP, FAAN, FANA

Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.